Quick Order

Interferon beta/IFN-beta/IFNB1 Rabbit PAb , Antigen Affinity Purified

    DatasheetReviewsRelated ProductsProtocols
    Human IFNB1 Antibody Product Information
    Immunogen:Recombinant Human IFN beta protein (Catalog#10704-HNAC)
    Clone ID:
    Ig Type:Rabbit IgG
    Concentration:
    Formulation:0.2 μm filtered solution in PBS with 5% trehalose
    Preparation:Produced in rabbits immunized with purified, recombinant Human IFN beta (rh IFN beta; Catalog#10704-HNAC; NP_002167.1; Met 1-Asn 187). IFN beta specific IgG was purified by Human IFN beta affinity chromatography.
    Other IFNB1 Antibody Products
    Immunochemical staining of human CCNF in human brain with rabbit polyclonal antibody (1 µg/mL, formalin-fixed paraffin embedded sections).
    Interferon beta/IFN-beta/IFNB1 Background

    Interferons (IFNs) are natural glycoproteins belonging to the cytokine superfamily, and are produced by the cells of the immune system of most vertebrates in response to challenges by foreign agents such as viruses, parasites and tumor cells. Interferon-beta (IFN beta) is an extra-cellular protein mediator of host defense and homeostasis. IFN beta has well-established direct antiviral, antiproliferative and immunomodulatory properties. Recombinant IFN beta is approved for the treatment of relapsing-remitting multiple sclerosis. The recombinant IFN beta protein has the theoretical potential to either treat or cause autoimmune neuromuscular disorders by altering the complicated and delicate balances within the immune system networks. It is the most widely prescribed disease-modifying therapy for multiple sclerosis (MS). Large-scale clinical trials have established the clinical efficacy of IFN beta in reducing relapses and slowing disease progression in relapsing-remitting MS. IFN beta therapy was shown to be comparably beneficial for opticospinal MS (OSMS) and conventional MS in Japanese. IFN beta is effective in reducing relapses in secondary progressive MS and may have a modest effect in slowing disability progression. In addition to the common antiviral activity, IFN beta also induces increased production of the p53 gene product which promotes apoptosis, and thus has therapeutic effect against certain cancers. The role of IFN-beta in bone metabolism could warrant its systematic evaluation as a potential adjunct to therapeutic regimens of osteolytic diseases. Furthermore, IFN beta might play a beneficial role in the development of a chronic progressive CNS inflammation.

    Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

    Human Interferon beta/IFN-beta/IFNB1 References
  • Kohriyama T, et al. (2008) Interferon-beta treatment for multiple sclerosis and predictors of response. Nippon Rinsho. 66(6): 1119-26.
  • Stbgen JP. (2009) Recombinant interferon-beta therapy and neuromuscular disorders. J Neuroimmunol. 212(1-2): 132-41.
  • Abraham AK, et al. (2009) Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol. 77(12): 1757-62.
  • Product nameProduct name
    Size / Price
    Catalog: 10704-RP02-50
    List Price: 
    Price:      (You Save: )

    Datasheet & Documentation

    All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"